[Pharmacokinetics and biotransformation of N-propylajmaline hydrogen tartrate in man].
10 and 20 mg of N-Propyl-ajmalin-hydrogentartrate (N-PAB, Neo-Gilurytmal) were administered i.v. and orally respectively to healthy volunteers. In the study 14C-labelled N-PAB was used. The pharmacokinetics and the metabolic behaviour was examined. A fast and complete absorption of the compound could be observed. The bioavailability was 78%. The terminal plasma elimination half-life (beta-phase) was in the range of 4 to 6 hours. A total of 33% of the administered radioactivity was excreted via the kidney. 35 to 48% of the radioactivity found in urine was unchanged N-PAB. The excretion-kinetics of the three main metabolites as well as of the parent compound were determined. The possible presence of non-metabolizers is suggested.
D000328:Adult; D000404:Ajmaline / Q000031:analogs & derivatives*; D001711:Biotransformation; D001798:Blood Proteins / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008297:Male; D008954:Models, Biological; D011219:Prajmaline / Q000097:blood / Q000378:metabolism*; D011485:Protein Binding
D001798:Blood Proteins; D000404:Ajmaline; D011219:Prajmaline
Pharmakokinetik und Biotransformation von N-Propyl-ajmalin-hydrogentartrat beim Menschen.